Werfen approaches 2 billion in revenue after growing 9% in 2021
The Barcelona-based family group specializing in diagnostics and healthcare material has invested 111 million euros in R&D in the last year, during which it has accessed the capital market for the first time and unified its brand on a global scale
Increasing size is one of the great challenges for the business fabric.Werfen is on its way to joining the select group of Catalan companies that bill more than 2,000 million euros a yearafter having closed the 2021 fiscal year with a turnover of 1,854 million euros. The Rubiralta family company has grown by 9.3% thanks to the good evolution of all its business lines and all the geographies where it operates, an increase that adds to the 15% growth registered in 2020. Werfen is a benchmark in the production of sanitary material for hospitals and laboratories and one of the global leaders in diagnostic solutions. It is estimated that more than 1.8 million daily samples are analyzed with reagents and systems developed by the company. Headquartered in one of the skyscrapers of Plaza Europa in L'Hospitalet, Werfen has benefited from the fStrong increase in demand for tests related to the diagnosis of the pandemic"LThe sale of molecular biology tests for the detection of COVID-19 in Spain and Portugal has consolidated Western Europe as the main geographical market for Werfen," says the company, which has obtained 47% of its revenue in this geographical area. North America generates 25% of the business and Asia 16%.The group chaired by Marc Rubiralta has significantly improved its earnings, al iincrease its net profit by 39%, reaching 363 million euros. EBITDA has also climbed 25%, with a record figure of 599 million. In its R&D laboratories alone, Werfen has executed investments of 111 million, a 5% increase. The group's global investment, counting the amount allocated to fixed assets, amounts to 221 million.
"Our work has an impact on every patient. This is why Werfen exists and why our clients trust us. Werfen is proud to have managed to secure supply to hospitals and laboratories despite the persistent stress on global supply chains thanks to the commitment of the company and all its employees," says Rubiralta.
The company is a supplier to hospitals and laboratories worldwide. For the first time, last October Werfen placed a 300 million bond on the capital markets, which allowed it to refinance all its debt and received an investment grade rating from credit agencies. Another of the year's milestones was the project to unify its name and brand with a new global corporate identity, as until now it had operated under different names in each market. Werfen has a direct presence in about 30 countries and operates in about a hundred through distributors, with a workforce of 5,640 employees and production centers in Catalonia, England, the United States, Germany. Its three major divisions are in vitro diagnostic tests, third-party manufacturing of reagents and biomaterials, and medical devices, such as drug infusion pumps.
Add The New Barcelona Post as your preferred Google source for free
